YRBAF yields 4434.59% · JNJ yields 2.13%● Live data
📍 YRBAF pulled ahead of the other in Year 1
Combined, YRBAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YRBAF + JNJ for your $10,000?
Yorbeau Resources Inc. engages in the acquisition, exploration, and development of mineral properties in Canada. It explores for gold, silver, copper, zinc, and other base metals. The company holds 100% interests in the Rouyn property that consists of 1 mining concession and 94 claims having a total area of 2,684.88 hectares (ha) located in the south of Rouyn-Noranda, Québec; the Scott Lake property comprises three non-contiguous claim blocks consisting of 123 complete or partial claim cells covering an area of approximately 6,089 ha located in the townships of Lévy, Scott, and Obalski in northwestern Québec; and the Estrades-Caribou property, which consists of three contiguous claim blocks totaling 118 claims located in the Estrées Township in Québec. It also owns 100% interests in the Beschefer property that comprises 128 claims located in the Beschefer Township of northwestern Quebec; the Selbaie West property consists of 105 claims located in the Carheil and Brouillan townships in Québec; the Landrienne property, which consists of 59 claims located in the Landrienne Township in Québec; the Lemoine property comprising 102 claims located in the Lemoine, Rinfret, and Dollier townships in Québec; and the Castagnier property. In addition, the company holds interests in the Joutel-Explo Zinc project consisting of 118 claims and 1 mining concession; the Gemini-Turgeon projects comprises 189 claims; and the Allard property, which includes 43 claims located in the Abitibi region of Québec. Yorbeau Resources Inc. was incorporated in 1984 and is headquartered in Montreal, Canada.
Full YRBAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.